Glenmark Pharmaceuticals, a research-driven global pharmaceutical company, has announced the launch of TEVIMBRA® (tislelizumab) in India, following approval by the Central Drugs Standard Control Organization (CDSCO). This marks Glenmark’s entry into the field of immuno-oncology in India, representing a significant milestone in expanding its innovative oncology portfolio.
Developed by BeiGene (now BeOne Medicines), a global leader in oncology, TEVIMBRA is a next-generation anti-PD-1 monoclonal antibody. It is indicated for:
First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and
Second-line monotherapy for both locally advanced/metastatic NSCLC and esophageal squamous cell carcinoma (ESCC).
This launch brings a differentiated immunotherapy option to Indian oncologists and patients, addressing two of the most prevalent and hard-to-treat cancers in the country. NSCLC accounts for more than 80% of lung cancer cases, while ESCC is the dominant histological subtype of esophageal cancer in India.
“Through the launch of TEVIMBRA, Glenmark is fulfilling its commitment to transform cancer care in India by introducing globally recognized immunotherapies that are now within reach of Indian patients,” said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals. “As cancer incidence continues to rise, we are proud to provide a treatment backed by strong science, established safety and efficacy, and the potential to make a real impact on patient lives.”
He added, “Immuno-oncology holds tremendous promise for treating advanced, difficult-to-manage cancers. Our entry into this field marks a turning point in our mission to develop an oncology portfolio that is not only innovative and evidence-based but also equitable and patient-focused.”